Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice

This study has been terminated.
(Terminated after FDA agreement.)
Sponsor:
Collaborator:
North America Pediatric Renal Trials and Collaborative Studies (NAPRTCS)
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier:
NCT01134315
First received: May 28, 2010
Last updated: May 17, 2013
Last verified: May 2013

May 28, 2010
May 17, 2013
June 2010
May 2012   (final data collection date for primary outcome measure)
Percentage of Participants With at Least One Incidence of Hypercalcemia [ Time Frame: Monitored from time of informed consent through end of study + 30 days (total of 745 days). ] [ Designated as safety issue: Yes ]
Hypercalcemia was defined as calcium >10.2 mg/dL. Percentage of participants with hypercalcemia is presented for the overall population, the subgroup of participants in the study for less than 3 months, and those in the study for greater than or equal to 3 months.
Hypercalcemia [ Time Frame: 3 to 36 months ] [ Designated as safety issue: Yes ]
The incidence of hypercalcemia (calcium > 10.2 mg/dL)
Complete list of historical versions of study NCT01134315 on ClinicalTrials.gov Archive Site
  • Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious AEs (SAEs), Deaths and Discontinuations Due to AEs [ Time Frame: Monitored from time of informed consent through end of study + 30 days (total of 745 days). ] [ Designated as safety issue: Yes ]
    AE: any untoward medical occurrence that does not necessarily have a causal relationship with treatment; any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered causally related to the use of the product (either paricalcitol or calcitriol); can result from use of the drug as stipulated in the labeling, as well as from accidental or intentional overdose, drug abuse, or drug withdrawal; any worsening of a pre-existing condition or illness. Severity was categorized as mild, moderate, or severe. SAE: AE that results in the death; is life-threatening; results in hospitalization or prolongation of hospitalization; is a congenital anomaly; results in persistent or significant disability/incapacity; is an important medical event requiring medical or surgical intervention to prevent serious outcome; is a spontaneous or elective abortion. For more details, please see the AE section of this record.
  • Mean Baseline (BL) and Change From Baseline in Potassium, Sodium, Chloride, Bicarbonate at Final Visit (FV) [ Time Frame: Baseline, Final Visit (defined as the last post-baseline observation, up to end of study [715 days]) ] [ Designated as safety issue: Yes ]
    Normal ranges for these chemistry measurements varied according to the age of the participant.
  • Mean Baseline (BL) and Change From Baseline in Calcium, Inorganic Phosphate (IP), Blood Urea Nitrogen (BUN), Creatinine at Final Visit (FV) [ Time Frame: Baseline, Final Visit (defined as the last post-baseline observation, up to end of study [715 days]) ] [ Designated as safety issue: Yes ]
    Normal ranges for these chemistry measurements varied according to the age of the participant.
  • Mean Baseline and Change From Baseline in 25-Hydroxy Vitamin D3 at Final Visit (FV) [ Time Frame: Baseline, Final Visit (defined as the last post-baseline observation, up to end of study [715 days]) ] [ Designated as safety issue: Yes ]
    Normal ranges for these chemistry measurements varied according to the age of the participant.
  • Mean Baseline and Change From Baseline in 1,25-Dihydroxy Vitamin D3 at Final Visit (FV) [ Time Frame: Baseline, Final Visit (defined as the last post-baseline observation, up to end of study [715 days]) ] [ Designated as safety issue: Yes ]
    Normal ranges for these chemistry measurements varied according to the age of the participant.
  • Mean Baseline and Change From Baseline in Parathyroid Hormone at Final Visit (FV) [ Time Frame: Baseline, Final Visit (defined as the last post-baseline observation, up to end of study [715 days]) ] [ Designated as safety issue: Yes ]
    Normal ranges for these chemistry measurements varied according to the age of the participant.
  • Mean Baseline and Change From Baseline in Albumin at Final Visit (FV) [ Time Frame: Baseline, Final Visit (defined as the last post-baseline observation, up to end of study [715 days]) ] [ Designated as safety issue: Yes ]
    Normal ranges for these chemistry measurements varied according to the age of the participant.
  • Adverse Events [ Time Frame: 3 to 36 months ] [ Designated as safety issue: Yes ]
    The incidence of adverse events including events leading to patient death and hospitalizations
  • Chemistry lab value change [ Time Frame: 3 to 36 months ] [ Designated as safety issue: Yes ]
    The change from baseline in chemistry measurements
Not Provided
Not Provided
 
Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice
A Prospective, Multicenter Study to Evaluate the Safety of Paricalcitol Capsules as Determined by Hypercalcemia in Pediatric Patients Ages 0 to 16 With Chronic Kidney Disease (CKD) Stage 5 Receiving Peritoneal Dialysis (PD) Within Current Clinical Practice

The objective of this study was to observe the safety of paricalcitol utilization in pediatric participants (ages 0 to 16 years old) being treated for secondary hyperparathyroidism (SHPT). Participants were to be followed for a minimum of 3 months and up to approximately 36 months to monitor the incidence of hypercalcemia (high calcium levels in blood).

Investigators were free to determine the appropriate therapy for each participant based on clinical judgment. Decisions to prescribe paricalcitol or calcitriol were made independently prior to enrollment of participants in this observational study.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

This was a multicenter, United States only study of pediatric (0 to 16 years) males and females receiving peritoneal dialysis, treated in a routine clinical setting. Patients were recruited from private nephrology practices or hospitals.

  • Secondary Hyperparathyroidism
  • End-Stage Renal Disease
  • Drug: Paricalcitol
    Other Names:
    • ABT-358
    • Zemplar
  • Drug: Calcitriol
  • Paricalcitol
    Pediatric participants who received paricalcitol capsules to treat secondary hyperparathyroidism (SHPT). Paricalcitol was prescribed by each physician under the usual and customary practice of that physician.
    Intervention: Drug: Paricalcitol
  • Calcitriol
    Pediatric participants who received calcitriol to treat secondary hyperparathyroidism (SHPT). Calcitriol was prescribed by each physician under the usual and customary practice of that physician.
    Intervention: Drug: Calcitriol
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
61
May 2012
May 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or female between 0 to 16 years of age (inclusive), on peritoneal dialysis for at least 30 days.
  2. The patient has a history of secondary hyperparathyroidism as defined by having initiated a vitamin D receptor activator to treat an elevated parathyroid hormone level.
  3. The patient is attending a site associated with North America Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Dialysis Registry.
  4. Patient and the patient's parent or legal guardian must voluntarily sign and date an informed consent and/or assent, approved by the local Independent Ethics Committee/Institutional Review Board, prior to the initiation of any screening or study-specific procedures.
  5. Patient has received paricalcitol or calcitriol for a minimum of 10 days.

Exclusion Criteria:

  1. Patient is scheduled for a kidney transplant within 3 months.
  2. Patient is expected to stop peritoneal dialysis within 3 months.
  3. Patient is expected to transfer to hemodialysis within 3 months.
  4. Patient is planning to be enrolled in an investigational study where the drug and/or dose are unknown to the investigator within the first 3 months from the date of patient enrollment.
Both
up to 16 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01134315
P12-053
No
AbbVie ( AbbVie (prior sponsor, Abbott) )
AbbVie (prior sponsor, Abbott)
North America Pediatric Renal Trials and Collaborative Studies (NAPRTCS)
Study Director: Ann Eldred, MD AbbVie
AbbVie
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP